{"id":"W4318693852","doi":"10.1200/jco.22.02186","title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Medicine; Afatinib; Clinical endpoint; Internal medicine; Oncology; Osimertinib; Lung cancer; Hazard ratio; Cancer; Clinical trial; Stage (stratigraphy); Adenocarcinoma; Confidence interval; Erlotinib; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01099146,0.001157071,0.002372448,0.0005244666,0.0003329028,0.001250963,0.0006607198,0.0007117833,0.002944604],"category_scores_gemma":[0.005292097,0.0004487956,0.002699432,0.0007062494,0.000572626,0.0009492388,0.0003848812,0.002235918,0.0005120263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005666292,"about_ca_system_score_gemma":0.001328733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007034809,"about_ca_topic_score_gemma":0.00282966,"domain_scores_codex":[0.9962788,0.002747833,0.0002125078,0.000198101,0.0003891496,0.0001735555],"domain_scores_gemma":[0.9970574,0.001149757,0.001045994,0.0002665804,0.0002287547,0.0002514941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8066642,0.005719726,0.009638718,0.002713992,0.00710055,0.00008941654,0.0001975913,0.001851958,0.006570023,0.0006506802,0.01011522,0.1486877],"study_design_scores_gemma":[0.8041613,0.1139385,0.04052779,0.0004543133,0.01397036,0.0002496685,0.0001069362,0.00207714,0.003118172,0.0008592094,0.02044334,0.00009330994],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9320486,0.03648473,0.004046806,0.002657985,0.0009084736,0.00587705,0.01027898,0.0002010933,0.007496344],"genre_scores_gemma":[0.9472024,0.01663206,0.008352847,0.002919956,0.001390389,0.006381709,0.01198285,0.00009770562,0.005040138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01099146,"threshold_uncertainty_score":0.05812913,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1084029731460099,"score_gpt":0.5189698770640995,"score_spread":0.4105669039180896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}